Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML.

Blood AdvSep 6, 2026
Clinical ResearchHematologyOncology (Medical)Open access

Nicholas J Short, Hagop Kantarjian, Naval Daver et al.

✦ AI-curated · Sources linked

In 30 seconds

This phase II clinical trial evaluated the long-term outcomes of azacitidine, venetoclax, and gilteritinib in 30 adults with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) unfit for intensive chemotherapy. The study found a complete remission rate of 96%, with median relapse-free survival and overall survival of 23.4 and 29.7 months, respectively.

Key findings

  • The complete remission rate was 96%, with 47% of patients undergoing allogeneic HSCT in first remission.
  • Median relapse-free survival was 23.4 months, and overall survival was 29.7 months.
  • 3-year relapse-free survival and overall survival rates were 43% and 46%, respectively.
  • Among FLT3-ITD-mutated AML patients, median relapse-free survival was 17.0 months.

Why it matters

The findings suggest that the triplet regimen of azacitidine, venetoclax, and gilteritinib can lead to durable remissions and improved survival in patients with FLT3-mutated AML, highlighting the need for further randomized studies to compare this approach with standard treatments.

Source

PubMed · PMID 42200455Free full text on PubMed Central

Published in Blood Adv. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.